Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies/ml initiated on elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate

Very high baseline HIV-1 RNA viral loads require potent and robust antiretroviral regimens to achieve virological suppression. The coformulated single tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) is recommended by the US Department of Healt...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2016-01, Vol.21 (2), p.175-180
Main Authors: Adams, Jessica L, Byrne, Dana, Pepe, Rosalie, Gray, Anastasia, Baxter, John D
Format: Article
Language:English
Subjects:
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - therapeutic use
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use
Female
HIV Infections - blood
HIV Infections - drug therapy
HIV Infections - virology
HIV-1 - genetics
Humans
Lentivirus
Male
Middle Aged
Retroviridae
RNA, Viral - blood
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Very high baseline HIV-1 RNA viral loads require potent and robust antiretroviral regimens to achieve virological suppression. The coformulated single tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) is recommended by the US Department of Health and Human Services for the treatment of HIV-1 in treatment-naive adults and adolescents regardless of baseline CD4(+) T-cell count and viral load. We report two cases of HIV-infected, treatment-naive patients, with baseline HIV-1 RNA viral loads >1,000,000 copies/ml who were initiated on the single tablet regimen EVG/COBI/FTC/TDF, but failed to attain viral load suppression and developed resistance to the components of EVG/COBI/FTC/TDF.
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP2987